RETRACTED ARTICLE: Efficacy of Menatetrenone (Vitamin K2) against Non-Vertebral and Hip Fractures in Patients with Neurological Diseases
- 96 Downloads
Background and objective: Patients with neurological diseases such as Alzheimer’s disease, stroke and Parkinson’s disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases.
Methods: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed.
Results: Three RCTs of patients with Alzheimer’s disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson’s disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment.
Conclusion: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.
KeywordsBone Mineral Density Osteocalcin Menatetrenone Femoral Neck Width Respective Relative Risk
No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.
- 1.The WHO Scientific Group. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003; 921: 86–109Google Scholar
- 15.Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 4.2.4. [updated March 2005]. Chichester: John Wiley & Sons Ltd, 2005Google Scholar
- 17.Orimo H, Fujita T, Onomura T, et al. Clinical evaluation of soft capsule menatetrenone (Ea-0167) in the treatment of osteoporosis: late phase II dose study [in Japanese]. J New Remedies Clinics 1992; 41: 1249–79Google Scholar
- 32.Orimo H, Fujita T, Onomura T, et al. Clinical evaluation of Ea-0167 (menatetrenone) in the treatment of osteoporosis: phase III double-blind multicenter comparative study with alfacalcidol [in Japanese]. Clin Eval 1992; 20: 45–100Google Scholar